Polyalanine and Polyglutamine Diseases: Possible Common Mechanisms?

Genetic Instabilities and Neurological Diseases

Volumn , Issue , 2006, Pages 487-513

  Abu Baker, Aida ^a   Rouleau, Guy A ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846414846     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369462-1/50034-X     Document Type: Chapter

References (220)

1. Abrams M.T., Reiss A.L., Freund L.S., Baumgardner T.L., Chase G.A., Denckla M.B. Molecular-neurobehavioral associations in females with the fragile X full mutation. Am. J. Med. Genet. 1994, 51:317-327.
2. Mulley J.C., Yu S., Loesch D.Z., Hay D.A., Donnelly A., et al. FRAXE and mental retardation. J. Med. Genet. 1995, 32:162-169.
3. Harding A.E. Friedreich's ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981, 104:589-620.
4. Harper P.S. Myotonic Dystrophy 1989, Saunders, London.
5. Greenfield J.G. The Spino-cerebellar Degenerations 1954, 112. C.C. Thomas, Springfield IL.
6. Holmes S.E., O'Hearn E.E., McInnis M.G., Gorelick-Feldman D.A., Kleiderlein J.J., et al. Expansion of a novel CAG trinucleotide repeat in the 5? region of PPP2R2B is associated with SCA12. Nat. Genet. 1999, 23:391-392.
7. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.
8. Muragaki Y., Mundlos S., Upton J., Olsen B.R. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 1996, 272:548-551.
9. Goodman F.R., Mundlos S., Muragaki Y., Donnai D., Giovannucci-Uzielli M.L., Lapi E., Majewski F., McGaughran J., McKeown C., Reardon W., et al. Synpolydactyly pheno-types correlate with size of expansions in HOXD13 polyalanine tract. Proc. Natl. Acad. Sci. USA 1997, 94:7458-7463.
10. Mundlos S., Otto F., Mundlos C., Mulliken J.B., Aylsworth A.S., Albright S., Lindhout D., Cole W.G., Henn W., Knoll J.H., Owen M.J., Mertelsmann R., Zabel B.U., Olsen B.R. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997, 89:773-779.
11. Brais B., Bouchard J.P., Xie Y.G., Rochefort D.L., Chretien N., Tome F.M., Lafreniere R.G., Rommens J.M., Uyama E., Nohira O., Blumen S., Korczyn A.D., Heutink P., Mathieu J., Duranceau A., Codere F., Fardeau M., Rouleau G.A. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 1998, 18:164-167.
12. Brown S.A., Warburton D., Brown L.Y., Yu C.-Y., Roeder E.R., Stengel-Rutkowski S., Hennekam R.C.M., Muenke M. Holoprosencephaly due to mutation in ZIC2 a homologue of Drosophila odd-paired. Nat. Genet. 1998, 20:180-183.
13. Mortlock D.P., Post L.C., Innis J.W. The molecular basis of hypodactyly (Hd); A deletion in Hoxa 13 leads to arrest of digital arch formation. Nat. Genet. 1996, 13:284-289.
14. Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., Bisceglia L., Zelante L., Nagaraja R., Porcu S., et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat. Genet. 2001, 27:159-166.
15. Stromme P., Mangelsdorf M.E., Shaw M.A., Lower K.M., Lewis S.M., Bruyere H., Lutcherath V., Gedeon A.K., Wallace R.H., Scheffer I.E., Turner G., Partington M., Frints S.G., Fryns J.P., Sutherland G.R., Mulley J.C., Gecz J. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat. Genet. 2002, 30:441-445.
16. Laumonnier F., Ronce N., Hamel B.C., Thomas P., Lespinasse J., Raynaud M., Paringaux C., Van Bokhoven H., Kalscheuer V., Fryns J.P., Chelly J., Moraine C., Briault S. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am. J. Hum. Genet. 2002, 71:1450-1455.
17. Amiel J., Laudier B., Attie-Bitach T., Trang H., De Pontual L., Gener B., Trochet D., Etchevers H., Ray P., Simonneau M., et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat. Genet. 2003, 33:459-461.
18. Gusella J.F., MacDonald M.E. Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 2000, 1:109-115.
19. Cummings C.J., Zoghbi H.Y. Fourteen and counting: Unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 2000, 9:909-916.
20. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 1998, 273:9158-9167.
21. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. USA 2001, 98:15179-15184.
22. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 2000, 97:6763-6768.
23. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
24. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
25. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
26. Sanchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
27. Szebenyi G., Morfini G.A., Babcock A., Gould M., Selkoe K., Stenoien D.L., Young M., Faber P.W., MacDonald M.E., McPhaul M.J., Brady S.T. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003, 40:41-52.
28. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
29. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 2002, 295:1852-1858.
30. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 1998, 143:1883-1898.
31. Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 1999, 19:10338-10347.
32. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 1999, 8:673-682.
33. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., Marcelli M., Weigel N.L., Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 1999, 8:731-741.
34. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 2000, 275:8772-8778.
35. Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., Hartl F.U. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 2000, 97:7841-7846.
36. Satyal S.H., Schmidt E., Kitagawa K., Sondheimer N., Lindquist S., Kramer J.M., Morimoto R.I. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 2000, 97:5750-5755.
37. Cummings C.J., Mancini M.A., Antalffy B., DeFranco D.B., Orr H.T., Zoghbi H.Y. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 1998, 19:148-154.
38. Fernandez-Funez P., Nino-Rosales M.L., de Gouyon B., She W.C., Luchak J.M., Martinez P., Turiegano E., Benito J., Capovilla M., Skinner P.J., McCall A., Canal I., Orr H.T., Zoghbi H.Y., Botas J. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000, 408:101-106.
39. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
40. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
41. Alves-Rodrigues A., Gregori L., Figueiredo-Pereira M.E. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 1998, 21:516-520.
42. Paulson H.L. Protein fate in neurodegenerative proteinopathies: Polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet. 1999, 64:339-345.
43. Klionsky D.J., Ohsumi Y. Cytoplasm to vacuole protein transport. Annu. Rev. Cell Dev. Biol. 1999, 15:1-32.
44. Li X.J., et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995, 378:398-402.
45. Perez M.K., Paulson H.L., Pendse S.J., Saionz S.J., Bonini N.M., Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 1998, 143:1457-1470.
46. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T.F., Kato K., Rubinsztein D.C. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1829-1845.
47. Huang C.C., Faber P.W., Persichetti F., Mittal V., Vonsattel J.P., MacDonald M.E., Gusella J.F. Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 1998, 24:217-233.
48. Boutell J.M., Thomas P., Neal J.W., Weston V.J., Duce J., Harper P.S., Jones A.L. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 1999, 9:1647-1655.
49. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., Kimura T., Koide R., Nozaki K., Sano Y., Ishiguro H., Sakoe K., Ooshima T., Sato A., Ikeuchi T., Oyake M., Sato T., Aoyagi Y., Hozumi I., Nagatsu T., Takiyama Y., Nishizawa M., Goto J., Kanazawa I., Davidson I., Tanese N., Takahashi H., Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 2000, 26:29-36.
50. Shur S.T., Senut M.C., Whitelegge J.P., Faull K.F., Cuizon D.B., Gage F.H. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell Biol. 2001, 153:283-294.
51. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
52. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kertz O., Villalba A.M., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet. 2002, 31:47-54.
53. Kegel K.B., Meloni A.R., Yi Y., Kim Y.J., Doyle E., Cuiffo B.G., Sapp E., Wang Y., Qin Z.H., Chen J.D., Nevins J.R., Aronin N., DiFiglia M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 2002, 277:7466-7476.
54. Cha J.J. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23:387-392.
55. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
56. Taylor J.P., Taye A.A., Campbell C., Kazemi-Esfarjani P., Fischbeck K.H., Min K.T. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev. 2003, 17:1463-1468.
57. Hughes R.E., Lo R.S., Davis C., Strand A.D., Neal C.L., Olson J.M., Fields S. Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl. Acad. Sci. USA 2001, 98:13201-13206.
58. Steffan J., Thompson L. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin. Ther. Targets 2003, 7:201-213.
59. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H., Néri C. Reserveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005, 37:349-350.
60. Gunawardena S., Her L.S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., Sintasath L., Bonini N.M., Goldstein L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
61. Cornett J., Cao F., Wang C.E., Ross C.A., Bates G.P., Li S.H., Li X.J. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat. Genet. 2005, 37:198-204.
62. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
63. 10 reduced the toxicity of retenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors 2003, 18:65-72.
64. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
65. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F., Greenamyre J.T., Snyder S.H., Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 1999, 5:1194-1198.
66. Sawa A. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: Pathological cross-talk between the nucleus and the mitochondria?. J. Mol. Med. 2001, 79:375-381.
67. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
68. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
69. Ruan Q., Lesort M., MacDonald M.E., Johnson G.V.W. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 2004, 13:669-681.
70. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.-J., Castilho R.F., Brundin Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 2001, 14:1492.
71. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 2005, 102:2602-2607.
72. Chen H.K., Fernandez-Funez P., Acevedo S.F., Lam Y.C., Kaytor M.D., Fernandez M.H., Aitken A., Skoulakis E.M., Orr H.T., Botas J., Zoghbi H.Y. Interaction of akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003, 113:457-468.
73. Emamian E.S., Kaytor M.D., Duvick L.A., Zu T., Tousey S.K., Zoghbi H.Y., Clark H.B., Orr H.T. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003, 38:375-387.
74. Yazawa I. Aberrant phosphorylation of dentatorubral-pallidoluysian atrophy (DRPLA) protein complex in brain tissue. Biochem. J. 2000, 351:587-593.
75. Chan H.Y., Warrick J.M., Andriola I., Merry D., Bonini N.M. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 2002, 11:2895-2904.
76. Li Y., Wang H., Wang S., Quon D., Liu Y.W., Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. USA 2003, 100:259-264.
77. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
78. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., Heintz N., Yang X.W. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
79. Rousseau E., Dehay B., Ben-Haiem L., Trottier Y., Morange M., Bertolotti A. Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc. Natl. Acad. Sci. USA 2004, 101:9648-9653.
80. Temtamy S.A., McKusick V.A. The Genetics of Hand Malformations 1978, 465. Alan R. Liss (pub), New York.
81. Izpisua-Belmonte, Duboule Homeobox genes and pattern formation in the vertebrate limb. Dev. Biol. 1992, 152:26-36.
82. Brown L.Y., Brown S.A. Alanine tracts: The expanding story of human illness and trinucleotide repeats. Trends Genet. 2004, 20:51-58.
83. Dolle P., Izpisua-Belmonte J.C., Brown J., Tickle C., Duboule D. Hox genes and the morphogenesis of the vertebrate limb. Prog. Clin. Biol. Res. 1993, 383A:11-20.
84. Davies A.P., Capecchi M.R. A mutational analysis of the 5? HoxD genes: Dissection of genetic interactions during limb development in the mouse. Development 1996, 122:1175-1185.
85. Albrecht A.N., Kornak U., Boddrich A., Suring K., Robinson P.N., Stiege A.C., Lurz R., Stricker S., Wanker E.E., Mundlos S. A molecular pathogenesis for transcription factor associated polyalanine tract expansions. Hum. Mol. Genet. 2004, 13:2351-2359.
86. Halal F. The hand-foot-genital (hand-foot-uterus) syndrome: Family report and update. Am. J. Med. Genet. 1988, 30:793-803.
87. Utsch B., Becker K., Brock D., Lentze M.J., Bidlingmaier F., Ludwig M. A novel stable polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital syndrome: Proper function of poly(A)-harbouring transcription factors depends on a critical repeat length?. Hum. Genet. 2002, 110:488-494.
88. Goodman F.R., Bacchelli C., Brady A.F., Brueton L.A., Fryns J.P., Mortlock D.P., Innis J.W., Holmes L.B., Donnenfeld A.E., Feingold M., et al. Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am. J. Hum. Genet. 2000, 67:197-202.
89. Innis J.W., Mortlock D., Chen Z., Ludwig M., Williams M.E., Williams T.M., Doyle C.D., Shao Z., Glynn M., Mikulic D., Lehmann K., Mundlos S., Utsch B. Polyalanine expansion in HOXA13: Three new affected families and the molecular consequences in a mouse model. Hum. Mol. Genet. 2004, 13:2841-2851.
90. Jones Smith's Recognizable Patterns of Human Malformation 1997, W.B. Saunders Co., Philadelphia. 5th ed.
91. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
92. Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H., Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W., Nakamura T., Hayasaka K. Molecular analysis of congenital central hypoventilation syndrome. Hum. Genet. 2003, 114:22-26.
93. Weese-Mayer D.E., Berry-Kravis E.M., Zhou L., Maher B.S., Silvestri J.M., Curran M.E., Marazita M.L. Idiopathic congenital central hypoventilation syndrome: Analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in Phox2b. Am. J. Med. Genet. 2003, 123:267-278.
94. Matera I., Bachetti T., Puppo F., Di Duca M., Morandi F., Casiraghi G.M., Cilio M.R., Hennekam R., Hofstra R., Schober J.G., Ravazzolo R., Ottonello G., Ceccherini I. PHOX2B mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset central hypoventilation syndrome. J. Med. Genet. 2004, 41:373-380.
95. DeMyer W.E., Zeman W., Palmer C.G. Familial alobar holoprosencephaly (arhinencephaly) with median cleft lip and palate: Report of patient with 46 chromsomes. Neurology 1963, 13:913-918.
96. Brown L.Y., Odent S., David V., Blayau M., Dubourg C., Apacik C., Delgado M.A., Hall B.D., Reynolds J.F., Sommer A., Wieczorek D., Brown S.A., Muenke M. Holoprosencephaly due to mutations in ZIC2: Alanine tract expansion mutations may be caused by parental somatic recombination. Hum. Mol. Genet. 2001, 10:791-796.
97. Nagai T., Aruga J., Minowa O., Sugimoto T., Ohno Y., Noda T., Mikoshiba K. Zic2 regulates the kinetics of neurulation. Proc. Natl. Acad. Sci. USA 2000, 97:1618-1623.
98. Nagai T., Aruga J., Takada S., Gunther T., Sporle R., Schughart K., Mikoshiba K. The expression of the mouse Zic1, Zic2, and Zic3 gene suggests an essential role for Zic genes in body pattern formation. Dev. Biol. 1997, 182:299-313.
99. Brown L., Paraso M., Arkell R., Brown S. In vitro analysis of partial loss-of-function ZIC-2 mutations in holoprosencephaly: Alanine tract expansion modulates DNA binding and transactivation. Hum. Mol. Genet. 2004, 14:411-420.
100. Blumen S.C., Brais B., Korczyn A.D., Medinsky S., Chapman J., Asherov A., Nisipeanu P., Codere F., Bouchard J.P., Fardeau M., Tome F.M., Rouleau G.A. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann. Neurol. 1999, 46:115-118.
101. Prueitt, Zinn A fork in the road to fertility. Nat. Genet. 2001, 27:132-134.
102. Zlotogora J., Sagi M., Cohen T. The blepharophimosis, ptosis, and epicanthus inversus syndrome: Delineation of two types. Am. J. Hum. Genet. 1983, 35:1020-1027.
103. De Baere E., Beysen D., Oley C., Lorenz B., Cocquet J., De Sutter P., Devriendt K., Dixon M., Fellous M., Fryns J.P., Garza A., Jonsrud C., Koivisto P.A., Krause A., Leroy B.P., Meire F., Plomp A., Van Maldergem L., De Paepe A., Veitia R., Messiaen L. FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am. J. Hum. Genet. 2003, 72:478-487.
104. Caburet S., Demarez A., Moumme L., Fellows M., De Baere E., Veitia R.A. A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J. Med. Genet. 2004, 41:931-946.
105. Feinberg A.P., Leahy W.R. Infantile spasms: Case report of sex-linked inheritance. Dev. Med. Child Neurol. 1977, 19:524-526.
106. Bienvenu T., Poirier K., Friocourt G., Bahi N., Beaumont D., Fauchereau F., Ben Jeema L., Zemni R., Vinet M.C., Francis F., Couvert P., Gomot M., Moraine C., van Bokhoven H., Kalscheuer V., Frints S., Gecz J., Ohzaki K., Chaabouni H., Fryns J.P., Desportes V., Beldjord C., Chelly J. ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. Hum. Mol. Genet. 2002, 11:981-991.
107. Kato M., Das S., Petras K., Kitamura K., Morohashi K., Abuelo D.N., Barr M., Bonneau D., Brady A.F., Carpenter N.J., Cipero K.L., Frisone F., Fukuda T., Guerrini R., Iida E., Itoh M., Lewanda A.F., Nanba Y., Oka A., Proud V.K., Saugier-Veber P., Schelley S.L., Selicorni A., Shaner R., Silengo M., Stewart F., Sugiyama N., Toyama J., Toutain A., Vargas A.L., Yanazawa M., Zackai E.H., Dobyns W.B. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum. Mutat. 2004, 23:147-159.
108. Nasrallah I.M., Minarcik J.C., Golden J.A. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J. Cell Biol. 2004, 167:411-416.
109. Brais B., Xie Y.G., Sanson M., Morgan K., Weissenbach J., Korczyn A.D., Blumen S.C., Fardeau M., Tome F.M., Bouchard J.P., Rouleau G.A. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum. Mol. Genet. 1995, 4:429-434.
110. Tome F.M., Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. (Berlin) 1980, 49:85-87.
111. Rubinsztein D.C., Wyttenbach A., Rankin J. Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?. J. Med. Genet. 1999, 36:265-270.
112. Shanmugam V., Dion P., Rochefort D., Laganiere J., Brais B., Rouleau G.A. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Ann. Neurol. 2000, 48:798-802.
113. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
114. Abu-Baker A., Messaed C., Laganiere J., Gaspar C., Brais B., Rouleau G.A. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 2003, 12:2609-2623.
115. Calado A., Tome F.M.S., Brais B., Rouleau G.A., Kuhn U., Wahle E., Carmo-Fonseca M. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet. 2000, 9:2321-2328.
116. Bao Y.P., Cook L.J., O'Donovan D., Uyama E., Rubinsztein D.C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem. 2002, 277:12263-12269.
117. Fan X., Dion P., Laganiere J., Brais B., Rouleau G.A. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum. Mol. Genet. 2001, 10:2341-2351.
118. Albrecht A.N., Mundlos S. The other trinucleotide repeat: Polyalanine expansion disorders. Curr. Opin. Genet. Dev. 2005, 15:285-293.
119. Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 1994, 91:5355-5358.
120. Bates G.P., Mangiarini L., Davies S.W. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol. 1998, 6:699-714.
121. Lathrop R.H., Casale M., Tobias D.J., Marsh J.L., Thompson L.M. Modeling protein homopolymeric repeats: Possible polyglutamine structural motifs for Huntington's disease. Proc. Int. Conf. Intell. Syst. Mol. Biol. 1998, 6:105-114.
122. Cooper A.J., Sheu K.F., Burke J.R., Onodera O., Strittmatter W.J., Roses A.D., Blass J.P. Polyglutamine domains are substrates of tissue transglutaminase: Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?. J. Neurochem. 1997, 69:431-434.
123. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., Tsuji S. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 1998, 18:1111-1117.
124. Kahlem P., Green H., Dijan P. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin, containing expanded polyglutamine. Mol. Cell 1998, 1:595-601.
125. Lesort M., Chun W., Tucholski J., Johnson G.V. Does tissue transglutaminase play a role in Huntington's disease?. Neurochem. Int. 2002, 40:37-52.
126. Blondelle S.E., Forood B., Houghten R.A., Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. Biochemistry 1997, 36:8393-8400.
127. Forood B., Perez-Paya E., Houghten R.A., Blondelle S.E. Formation of an extremely stable polyalanine beta-sheet macromolecule. Biochem. Biophys. Res. Commun. 1995, 211:7-13.
128. Perutz M.F., Pope B.J., Owen D., Wanker E.E., Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. USA 2002, 99:5596-5600.
129. Rankin J., Wyttenbach A., Rubinsztein D.C. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem. J. 2000, 348:15-19.
130. Gaspar C., Jannatipour M., Dion P., Laganiere J., Sequeiros J., Brais B., Rouleau G.A. CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum. Mol. Genet. 2000, 9:1957-1966.
131. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
132. Rangone H., Humbert S., Saudou F. Huntington's disease: How does huntingtin, an anti-apoptotic protein, become toxic?. Pathol. Biol. (Paris) 2004, 52:338-342.
133. Rigamonti D., Bauer J.H., De Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2000, 20:3705-3713.
134. Burnett B., Li F., Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitinylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 2003, 12:3195-3205.
135. Scheel H., Tomiuk S., Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 2003, 12:2845-2852.
136. Helmlinger D., Hardy S., Sasorith S., Klein F., Robert F., Weber C., Miguet L., Potier N., Van Dorsselaer A., Wurtz J.-M., Mandel J.-L., Tora L., Devys D. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 2004, 13:1257-1265.
137. Hill M.E., Creed G.A., McMullan T.F., Tyers A.G., Hilton-Jones D., Robinson D.O., Hammans S.R. Oculopharyngeal muscular dystrophy: Phenotypic and genotypic studies in a UK population. Brain 2001, 124:522-526.
138. Schober R., Kress W., Grahmann F., Kellermann S., Baum P., Gunzel S., Wagner A. Unusual triplet expansion associated with neurogenic changes in a family with oculopharungeal muscular dystrophy. Neuropathologa 2001, 21:45-52.
139. Pou Serradell A., Lloreta J., Corominas J., Hammouda E., Urtizberea J., Richard P., Brais B. Oculopharyngeal muscular dystrophy: Study of patients from seven Spanish families with different GCG expansions in PABP2 gene. Neurologia 2004, 19:239-247.
140. Lavoie H., Debeane F., Trinh Q.D., Turcotte J.F., Corbeil-Girard L.P., Dicaire M.J., Saint-Denis A., Page M., Rouleau G.A., Brais B. Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Hum. Mol. Genet. 2003, 12:2967-2979.
141. Han K., Manley J.L. Functional domains of the Drosophila engrailed protein. EMBO J. 1993, 12:2723-2733.
142. Young E.T., Sloan J.S., Van Riper K. Trinucleotide repeats are clustered in regulatory genes in Saccharomyces cerevisiae. Genetics 2000, 154:1053-1068.
143. Wahle E. A novel poly(A)-binding protein acts as specificity factor in the second phase of messenger RNA polyadenylation. Cell 1991, 66:759-768.
144. Wahle E. Purification and characterization of a mammalian polyadenylate polymerase involved in the 3? end processing of messenger RNA precursors. J. Biol. Chem. 1991, 266:3131-3139.
145. Krause S., Fakan S., Weis K., Wahle E. Immunodetection of poly(A) binding protein II in the cell nucleus. Exp. Cell Res. 1994, 214:75-82.
146. Wahle E., Lustig A., Jeno P., Maurer P. Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides. J. Biol. Chem. 1993, 268:2937-2945.
147. Nemeth A., Krause S., Blank D., Jenny A., Jeno P., Lusting A., Wahle E. Isolation of genomic and cDNA clones encoding bovine poly(A) binding protein II. Nucleic Acids Res. 1995, 23:4034-4041.
148. Calado U., Kutay U., Kühn E., Wahle E., Carmo-Fonseca M. Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA 2000, 6:245-256.
149. Wahle E. Poly(A) tail length control is caused by termination of processive synthesis. J. Biol. Chem. 1995, 270:2800-2808.
150. Gorlach M., Burd C.G., Dreyfuss G. The mRNA poly(A)-binding protein: Localization, abundance, and RNA-binding specificity. Exp. Cell Res. 1994, 211:400-407.
151. Afonina E., Stauber R., Pavlakis G.N. The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J. Biol. Chem. 1998, 273:13015-13021.
152. Tome F.M., Chateau D., Helbling-Leclerc A., Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 1997, 7:S63-S69.
153. Davies J.E., Wang L., Garcia-Oroz L., Cook L.J., Vacher C., O'Donovan D.G., Rubinsztein D.C. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 2005, 6:672-677.
154. Fan X., Messaed C., Dion P., Laganiere J., Brais B., Karpati G., Rouleau G.A. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 2003, 30:244-251.
155. Abu-Baker A., Laganiere S., Fan X., Laganiere J., Brais B., Rouleau G.A. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy. Traffic 2005, 6:1-14.
156. Scheuermann T., Schulz B., Blume A., Wahle E., Rudolph R., Schwarz E. Trinucleotide expansions leading to an extended poly-l-alanine segment in the poly(A) binding protein PABPN1 cause fibril formation. Protein Sci. 2003, 12:2685-2692.
157. Onodera O., Burke J.R., Miller S.E., Hester S., Tsuji S., Roses A.D., Strittmatter W.J. Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells. Biochem. Biophys. Res. Commun. 1997, 238:599-605.
158. Iuchi G., Hoffner P., Verbeke P., Dijan, Green H. Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc. Natl. Acad. Sci. USA 2003, 100:2409-2414.
159. Benvivino A.E., Loll P.J. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel fibrils. Proc. Natl. Acad. Sci. USA 2001, 98:11955-11960.
160. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
161. Bao Y.P., Sarkar S., Uyama E., Rubinsztein D.C. Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. J. Med. Genet. 2004, 41:47-51.
162. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11:1107-1117.
163. Wyttenbach A., Carmichael J., Swartz J., Furlong R.A., Narain Y., Rankin J., Rubinsztein D.C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2898-2903.
164. Nakielny S., Dreyfuss G. Nuclear export of proteins and RNAs. Curr. Opin. Cell Biol. 1997, 9:420-429.
165. Tavanez J.P., Calado p., Braga J., Lafarga M., Carmo-Fonseca M. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 2005, 5:752-762.
166. Corbeil-Girard L.P., Klein A.F., Sasseville A.M., Lavoie H., Dicaire M.J., Saint-Denis A., Page M., Duranceau A., Codere F., Bouchard J.P., Karpati G., Rouleau G.A., Massie B., Langelier Y., Brais B. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis. 2005, 18:551-567.
167. Deleault N.R., Lucassen R.W., Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003, 16:717-720.
168. Neuwald A.F., Koonin E.V. Ataxin-2, global regulators of bacterial gene expression, and spliceosomal snRNP proteins share a conserved domain. J. Mol. Med. 1998, 76:3-5.
169. Burd C.G., Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994, 265:615-621.
170. Huynh D.P., Del Bigio M.R., Ho D.H., Pulst S.-M. Expression of ataxin 2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2 (SCA2). Ann. Neurol. 1999, 45:232-241.
171. Yue S., Serra H.G., Zoghbi H.Y., Orr H.T. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum. Mol. Genet. 2001, 10:25-30.
172. Irwin S., Vandelft M., Pinchev D., Howell J.L., Graczyk J., Orr H.T., Truant R. RNA association and nucleocyto-plasmic shuttling by ataxin-1. J. Cell Sci. 2005, 118:233-242.
173. Skinner P.J., Koshy B.T., Cummings C.J., Klement I.A., Helin K., Servadio A., Zoghbi H.Y., Orr H.T. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997, 389:971-974.
174. Dovey C.L., Varadaraj A., Wyllie A.H., Rich T. Stress responses of PML nuclear domains are ablated by ataxin-1 and other nucleoprotein inclusions. J. Pathol. 2004, 203:877-883.
175. Yamada M., Sato T., Shimohata T., Hayashi S., Igarashi S., Tsuji S., Takahashi H. Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases. Am. J. Pathol. 2001, 159:1785-1795.
176. Takahashi J., Fujigasaki H., Zander C., El Hachimi K.H., Stevanin G., Durr A., Lebre A.S., Yvert G., Trottier Y., The H., Hauw J.J., Duyckaerts C., Brice A. Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content. Brain 2002, 125:1534-1543.
177. Chai Y., Wu L., Griffin J.D., Paulson H.L. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J. Biol. Chem. 2001, 276:44889-44897.
178. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
179. Peters M.F., Nucifora F.C., Kushi J., Seaman H.C., Cooper J.K., Herring W.J., Dawson V.L., Dawson T.M., Ross C.A. Nuclear targeting of mutant Huntingtin increase toxicity. Mol. Cell Neurosci. 1999, 2:121-128.
180. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
181. Yang W., Dunlap J.R., Andrews R.B., Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 2002, 11:2905-2917.
182. Kim Y.-J., Noguchi Y.K., Hayashi T., Tsukahara T., Shimizu A.K. The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum. Mol. Genet. 2001, 10:1129-1139.
183. Bear D.G., Fomproix N., Soop T., Björkroth B., Masich S., Daneholt B. Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore. Exp. Cell Res. 2003, 286:332-344.
184. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 2000, 275:19831-19838.
185. Probst A., Tackmann W., Stoeckli H.R., Jerusalem F., Ulrich J. Evidence for a chronic axonal atrophy in oculopharyngeal "muscular dystrophy". Acta Neuropathol. (Berlin) 1982, 57:209-216.
186. Boukriche Y., Maisonobe T., Masson C. Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve 2002, 25:98-101.
187. Nakashima D., Nakajima H., Ishida S., Sugino M., Kimura F., Hanafusa T. Preferential distal muscle involvement in case of oculopharyngeal muscular dystrophy with (GCG) 13 expansion. Rinsho Shinkeigaku 2003, 43:560-563.
188. Dion P., Shanmugam V., Gaspar C., Messaed C., Meijer I., Toulouse A., Laganiere J., Roussel J., Rochefort D., Laganiere S., Allen C., Karpati G., Bouchard J.P., Brais B., Rouleau G.A. Transgenic expression of an expanded (GCG) 13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol. Dis. 2005, 3:528-536.
189. Codere F. Oculopharyngeal muscular dystrophy. Can. J. Ophthalmol. 1993, 28:1-2.
190. Duranceau A. Cricopharyngeal mytomy in the man-agement of neurogenic and muscular dysphagia. Neuromuscul. Disord. 1997, 7:S85-S89.
191. Mathieu J., Lapointe G., Brassard A., Tremblay C., Brais B., Rouleau G.A., Bouchard J.P. A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 1997, 7:S100-S104.
192. Sisodia S.S. Nuclear inclusions in glutamine repeat disders: Are they pernicious, coincidental, or beneficial?. Cell 1998, 95:1.
193. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
194. Orr H.T. Neurodegenerative disease: Neuron protection agency. Nature 2004, 431:747-748.
195. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
196. Kuemmerle S., Gutekunst C.A., Klein A.M., Li X.J., Li S.H., Beal M.F., Hersch S.M., Ferrante R.J. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 1999, 46:842-849.
197. Muchowski P.J. Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones?. Neuron 2002, 35:9-12.
198. Wirtschafter J.D., Ferrington D.A., McLoon L.K. Continuous remodeling of adult extraocular muscles as an explanation for selective craniofacial vulnerability in oculopharyngeal muscular dystrophy. J. Neuroophthalmol. 2004, 24:62-67.
199. Mouly V., Aamiri A., Bigot A., Cooper R.N., Di Donna S., Furling D., Gidaro R., Jacquemin V., Mamchaoui K., Negroni E., Perie S., Renault V., Silva-Barbosa S.D., Butler-Browne G.S. Acta Physiol. Scand. 2005, 184:3-15.
200. Sittler A., Wälter S., Wedemeyer N., Hasenbank R., Scherzinger E., Eickhoff H., Bates G., et al. SH3GL3 associates with the huntingtin exon 1 protein and promotes the formation of polyGln-containing protein aggregates. Mol. Cell 1998, 2:427-436.
201. Matilla A., Koshy B.T., Cummings C.J., Isobe T., Orr H.T., Zoghbi H.Y. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 1997, 389:974-978.
202. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function: New developments in Huntington's disease research. Trends Neurosci. 2001, 24:1-8.
203. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 2002, 277:41032-41037.
204. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., Kurosawa M., Nekooki M., Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 2004, 10:148-154.
205. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 2002, 8:143-149.
206. Sittler A., Lurz R., Lueder G., Priller J., Lehrach H., Hayer-Hartl M.K., Hartl F.U., Wanker E.E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1307-1315.
207. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., Ferrante R.J., Kristal B.S., Friedlander R.M. Minocycline inhibits caspase-independent and-dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100:10483-10487.
208. Chen M., One V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Monocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
209. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
210. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 1994, 36:882-888.
211. Heiser V., et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. USA 2002, 99:16400-16406.
212. Wood N.I., Morton A.J. Chronic lithium chloride treatment has variable effects on motor behavior and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 2003, 61:375-383.
213. Keene C.D., Rodrigues C.M.P., Eich T., Chhabra M.S., Steer C.J., Low W.C. Taurousodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2002, 99:10671-10676.
214. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T., Leeds P. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 2002, 4:129-136.
215. Lecerf J.-M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2001, 98:4764-4769.
216. Khoshnan A., Ko J., Patterson P.H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 2002, 99:1002-1007.
217. Xia H., Mao Q., Paulson H.L., Davidson B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 2002, 1008-1010.
218. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 2000, 275:10437-10442.
219. Kazantsev A., Walker H.A., Slepko N., Bear J.E., Preisinger E., Steffan J.S., Zhu Y.Z., Gertler F.B., Housman D.E., Marsh J.L., Thompson L.M. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 2002, 30:367-376.
220. Kerwitz Y., Kühn U., Lilie H., Knoth A., Scheuermann T., Friedrich H., Schwarz E., Wahle E. Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA. EMBO J. 2003, 22.